Carol Schafer has served as a member of the Board since January 2024. Ms. Schafer has more than 25 years of experience in healthcare investment banking and equity capital markets. Currently, Ms. Schafer serves as Managing Partner at Hyphen Advisors, LLC, a private advisory services company, which she founded in 2018. Ms. Schafer worked at Wells Fargo Securities from 2007 to 2018, most recently as Vice Chair, Equity Capital Markets. Prior to that, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals, Inc. from 2003 to 2007. Earlier, she held positions of increasing responsibility at J.P. Morgan, most recently serving as Managing Director of Equity Capital Markets. Ms. Schafer currently serves on the board of directors of Insmed Incorporated (NASDAQ: INSM), Kura Oncology, Inc. (NASDAQ: KURA) and she previously served on the board of directors of Five Prime Therapeutics, Inc. from 2019 until its acquisition by Amgen in April 2021, of Repare Therapeutics Inc. from 2019 to February 2026 and of Idera Pharmaceuticals, Inc. from 2018 to 2022. She holds an M.B.A. from New York University s Stern School of Business and a B.A. from Boston College. The Nominating Committee and the Board believe that Ms. Schafer is qualified to serve on the Board due to her extensive experience in financial services and capital markets, including capital raising and investor relations in the pharmaceutical industry, her finance and accounting background and her experience serving on boards of directors of other publicly-traded biopharmaceutical companies.